MEDIPOST, a Cambridge, Massachusetts-based biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies, said its parent company, MEDIPOST Co., Ltd., has closed $140 million in funding to accelerate late-stage clinical development and expand manufacturing and operational infrastructure.
The investment was completed at the parent-company level and is intended to support MEDIPOST Inc.’s anticipated U.S. Phase III clinical trial of an investigational mesenchymal stem cell (MSC) therapy aimed at treating symptomatic cartilage defects in patients with knee osteoarthritis. The company said trial initiation is anticipated in early 2026.
Skylake Equity Partners and Crescendo Equity Partners led the financing, with participation from a Korea-based growth equity fund. MEDIPOST said the funding will be used to expand scientific and operational capabilities, build infrastructure, and scale manufacturing processes as it prepares for late-stage evaluation in the U.S.
MEDIPOST positioned umbilical cord blood–derived stem cell therapies as offering biologically young cells, immune tolerance, and the potential for scalable, off-the-shelf manufacturing—attributes it says underpin the broader promise of regenerative medicine for inflammation-driven degenerative diseases.
Crescendo Equity Partners Managing Partner and CEO Kevin Lee said MEDIPOST has taken a disciplined, science- and rigor-driven approach as it prepares for the next phase of clinical development in the U.S.
KEY QUOTES
“The funding from Korea’s top growth equity funds fuels MEDIPOST’s global expansion as we prepare to advance into Phase III clinical evaluation in the U.S., with trial initiation anticipated in early 2026.” “Our mission is to develop regenerative therapies that are accessible, scalable and grounded in strong science and clinical rigor.”
Edward Ahn, PhD, Chief Executive Officer, MEDIPOST Inc.
“MEDIPOST Inc. has demonstrated a disciplined approach to regenerative medicine development, grounded in strong science and clinical rigor.”
Kevin Lee, PhD, Managing Partner & CEO, Crescendo Equity Partners
